Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MGNX

+ Watchlist+ Portfolio

MacroGenics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.97
52-Week Range
$1.32 – $5.08
Market Cap
$126.54M
P/E (TTM)
—
EPS (TTM)
-2.30
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.03
PEG Ratio
—
Return on Equity
-284.54%
Return on Assets
-14.58%
Gross Margin
-23.82%
Operating Margin
-48.83%
Profit Margin
-36.57%
Current Ratio
2.75
Debt/Equity
1.39
Total Debt
$34.86M
Free Cash Flow
$99.19M
Revenue Growth
-64.80%
Earnings Growth
—
Enterprise Value
$-126.28M

Market Snapshot

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies. The company develops innovative antibody-based therapeutics using proprietary technology platforms to create treatments for cancer and autoimmune diseases, with multiple product candidates in clinical development.